This is a guest post from RoosterBio, written by Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.
A “Golden Age” is defined as a period of time in a field where “great tasks are accomplished.” The ancient Greek philosopher Hesiod initially coined this phrase, and I think if he were alive today, he would agree with us that we are in a special time of technology convergence where innovations and advancements are progressing at an accelerating rate. The fields of Tissue Engineering and Regenerative Medicine are benefiting from these rapid technology advancements.
We are now at the beginnings of the Golden Age of BioFabrication. The last 20 years has seen steady progress in the Tissue Engineering field, but the cost and time it has taken to develop products based on these technologies has been prohibitive. Thus, only the best funded labs have been able to perform this very expensive R&D.
Within the last year, products such as high volume stem cells (via RoosterBio) and low cost bioprinters (from our collaborators BioBots) have been coming to market and dramatically reduce the cost, the time, and the complexity to fabricate three dimensional biological structures that are the precursors to tomorrow’s tissue engineered products.
By removing the technology and cost barriers and democratizing biofabrication technology, more labs can now afford to do the applied R&D, allowing more work to be accomplished faster, completely changing the equation of how labs function. This is accelerating the development of this entire field.
Walter Isaacson makes the point over and over in his new book, The Innovators,that collaboration between people and groups with complementary skill sets is essential to innovation and technology progress. At RoosterBio, we have always said that communication platforms (such as social networks, conferences, blogs, and journals) are also critical for those in a field to share knowledge and experiences, further progressing the thought convergence.
Want to be better informed than your competition? Get future stem cell industry updates.
RoosterBio (www.RoosterBio.com) is a biofabrication technology and products company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio has simplified and standardized how stem cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio’s innovative products are ushering in a new era of productivity and standardization into the field, where researchers spend newly found time and money performing more high-value experiments, accelerating the road to discovery in Regenerative Medicine.
BioInformant is the only research firm that has served the stem cell sector since it emerged. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, Goldman Sachs, and Becton Dickinson, BioInformant is your global leader in stem cell industry data. Click here to view our global strategic reports for the stem cell and cord blood industry.